SOURCE: Alchemia

Alchemia

April 07, 2014 20:07 ET

Alchemia Announces Presentation of Data on Its Discovery of a Potential New Cancer Stem Cell Therapeutic Target During the 2014 AACR Annual Meeting

BRISBANE, AUSTRALIA--(Marketwired - Apr 7, 2014) - Alchemia Limited (ASX: ACL), a drug discovery and development company, today announced that it will be presenting proprietary data at the American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9, in San Diego, California. The poster presentation entitled "The characterization of hyaluronan-related enzymes in breast cancer cell subpopulations," will be included in the session entitled "Cancer Stem Cell Niche and Metastasis," being held from 8:00 AM to 12:00 PM PDT on Tuesday, April 8th at the San Diego Convention Center.

The American Association for Cancer Research ("AACR") conference is one of the world's pre-eminent forums for the release of data on new cancer therapies. The AACR is a professional society of more than 24,000 laboratory and clinical scientists engaged in basic, translational and clinical cancer research in the United States and more than 60 other countries. Its annual meeting is attended by more than 15,000 scientists from around the world who share new and significant discoveries in the cancer field.

Alchemia's CSO, Dr. Tracey Brown is encouraged that this research was selected for a poster presentation. "The identification of this protein as a potential cancer stem cell therapeutic target places Alchemia in an elite group of companies that are trying to combat cancer by eradicating the treatment-resistant sub-population of tumor cells. If these preliminary data are further developed, any resulting therapeutics could potentially provide a great clinical benefit and increased survival to cancer sufferers," commented Dr. Brown.

The poster presentation made at the AACR Annual Meeting 2014 will be made available at http://www.alchemia.com.au/InvestorCentre/Presentations.aspx.

About Alchemia Limited

Alchemia is a drug discovery and development company marketing FDA approved fondaparinux, an injectible antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories. The Company is also developing a late stage oncology product pipeline with multiple ongoing trials through its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. Lead asset HA-Irinotecan is in a pivotal Phase III clinical trial for the treatment of metastatic colorectal cancer. HA-Irinotecan is also in two Phase II investigator-sponsored trials, one of which is in collaboration with Merck Serono combining HA-Irinotecan with Erbitux® (cetuximab). Alchemia is also exploring additional small molecule drug discovery targets via an internal discovery platform VAST, based on the Company's deep chemistry expertise. The VAST technology is being developed in collaboration with leading academic institutions and is partnered with AstraZeneca AB.

Erbitux® is a trademark of Merck KGaA.

Contact Information

  • Contact
    www.alchemia.com.au

    Alchemia Limited
    Thomas Liquard
    Chief Executive Officer
    Alchemia Limited
    Tel: +61 7 3340 0200

    Alchemia Limited
    Rosemary Cummins
    Investor Relations
    Alchemia Limited
    Tel: +61 4 0959 6164

    Investor Relations USA
    Candice Knoll
    Blueprint Life Science Group
    +1 415 375 3340 Ext. 105
    cknoll@bplifescience.com

    Media enquiries, Australia
    Emma Power or Rudi Michelson
    Monsoon Communications
    +61 3 9620 3333
    emmap@monsoon.com.au